HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCPC, CHPA Urge 'Modern' Risk Assessments For Sunscreen Ingredients

This article was originally published in The Rose Sheet

Executive Summary

FDA should revise its draft guidance on OTC sunscreen GRASE data to reflect modern toxicological risk assessment, say the Personal Care Products Council and Consumer Healthcare Products Association in a joint comment. The groups ask the agency to meet to discuss current approaches.

You may also be interested in...



Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations

PASS Coalition fails to find common ground with US FDA as the sunscreen access advocacy group urges significant changes to a draft guidance on safety testing for sunscreen ingredients.

ChromaDex Supplies ‘Healthy Aging’ Ingredient To Male Supplement Brand

ChromaDex Corp. agrees to supply its ‘healthy aging’ nicotinamide riboside ingredient Niagen to New York-based healthcare technology firm Roman Health Ventures, Inc., which plans to use it in its men’s supplement line. ChromaDex’ total sales in the first quarter rose 2% to $14.7m.

Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance

Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.

Topics

Related Companies

UsernamePublicRestriction

Register

RS020023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel